Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trump’s FDA Reform Agenda: Patient-Focused Approvals

Executive Summary

A posting on the transition website takes a much milder tone than the GOP platform issued over the summer.

You may also be interested in...



Top 16 From '16: Pink Sheet's Most Popular Stories

Big developments, key biopharma trends, and other topics that most intrigued and impacted our readers in 2016.

Woodcock Tries To Calm US FDA Staff Fears About Trump

CDER Director's' video advises focusing on the work and "keeping our heads down."

Trump’s Rx For The Drug Industry: Take Two And Have No Idea What Will Happen In The Morning

To call the incoming US president unpredictable would be an understatement, but that doesn’t mean that industry shouldn’t know what to expect.

Related Content

Topics

UsernamePublicRestriction

Register

PS119500

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel